Focus on cost containment is intensifying. It has become essential to support the value of pharmaceuticals and medical devices with economic and outcomes evidence for both internal management and planning, and to inform submissions for reimbursement listing. Acquiring market intelligence and understanding the impact of therapies and treatment options are vital in the disease management decision-making process throughout product lifecycles.
IMS Pricing and Market Access (P&MA), formerly M-TAG Pty Ltd, is a market leader in providing health economics and outcomes research for Australian and regional clients. We deliver evidence-based consulting solutions that inform confident decision-making about pricing and market access issues.
-
the best strategy to adopt for specific reimbursement submissions
-
quantified evidence depicting the impact of changes in government policy relating to product sales and revenue
-
strategies to minimise market erosion by encroaching generics
-
tactics to maximise brand price premium for your portfolio
-
medico-market strategies for creative product promotion.
IMS consultants help clients to achieve strategic goals and objectives by leveraging experience and unparalleled resources with cutting-edge methodologies that power the data–information–knowledge continuum.
Our consultants are experts in creating evidence-based solutions and are trusted advisors to the health sector’s most eminent organisations. We help to optimise each stage of the product lifecycle and bring new perspectives and value-added solutions to issues faced by our clients.